Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and IrinotecanChiara Cremolini, Daniele Santini, Elena Conca et al.|JAMA Oncology|2018Cited by 418
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN StudyEric Van Cutsem, Alberto Zaniboni, Erika Martinelli et al.|The Oncologist|2018Cited by 143